Abstract:Objective To investigate the anti-cancer efficacy and mechanism of sorafenib and 5-fluorouracil (5-FU) therapy in vitro using the HCC cell line MHCCLM3.Methods The effects of somfenib and 5-FU,alone or in combination,on the proliferation of MHCCLM3 cells were evaluated by cell viability assays.Combined-effects analyses were conducted according to the median-effect principle established by Chou and Talalay.Effects on cell cycle distributions were tested by flow cytometry and expression of proteins related to the RAF/MEK/ERK and STAT3 signaling pathways and cyclinD1 were tested by western blotting.Results Sorafenib and 5-FU alone or in combination displayed significant efficacy in inhibiting proliferation of the MHCCLM3 cells,with the following inhibition rates:somfenib:46.16％ ± 2.52％,5-FU:28.67％ ± 6.16％,and sorafenib + 5-FU:22.59％ ± 6.89％.The somfenib + 5-FU combination did not provide better results than treatment with either drag alone.The combination index values of the sorafenib and 5-FU treatments were mainly greater than 1,indicating that the two agents induced antagonistic,instead of synergistic,effects on the MHCCLM3 cells.In addition,the MHCCLM3 cells were less semitive to 5-FU when administrated in combination with sorafenib,as evidenced by the half inhibitory concentration (IC50) significantly increasing from (102.86 ± 27.84) mg/L to (178.61 ± 20.73) mg/L (P =0.003).Sorafenib alone induced G1 phase arrest (increasing from 44.73％ ± 1.63％ to 65.80％ ± 0.56％; P ＜ 0.001) and significantly decreased the proportion of cells in S phase (decreasing from 46.63％ ± 0.65％ to 22.83％ ± 1.75％; P ＜ 0.01),as well as down-regulated cyclinD1 expression (0.57 ± 0.03-fold change vs.untreated control group; P ＜ 0.01).5-FU alone up-regulated cyclinD1 expression (1.45 ± 0.12-fold change vs.untreated control group; P ＜ 0.01).Moreover,somfenib alone significantly inhibited the RAF/MEK/ERK and STAT3 pathways,with the fold-changes of p-C-RAF,p-ERK1/2 and p-STAT3 being 0.56 ±0.05,0.54 ± 0.02 and 0.36 ± 0.02,respectively (allP ＜ 0.01); 5-FU alone produced no significant effects on these pathways.Conclusion Administered alone,both somfenib and 5-FU exert anti-tumoral activity on in vitro cultured HCC cells.The somfenib + 5-FU combination treatment produces antagonistic,rather than synergistic,effects.Somfenib-inhibited RAF/MEK/ERK and STAT3 signaling and cyclinD1 expression may have induced the observed G lphase arrest and S phase reduction,thereby reducing the cells' sensitivity to 5-FU.

[Inhibition of Sorbaria Sorbifolia on Proliferarion of Hepatoma HepG-2 Cell Line].

BC047440 Gene Silencing Inhibits the Proliferation of HepG2 Cells

siRNA-mediated silencing of BC047440 gene inhibits proliferation of human HepG2 cell

[Anticancer Effect of SN-38 Combined with Sorafenib on Hepatocellular Carcinoma in Vitro and Its Mechanism].

Sorghumol triterpene inhibits the growth of circulating renal cancer cells by promoting cell apoptosis, G2/M cell cycle arrest and downregulating m-TOR/PI3K/AKT signalling pathway.

Anti-hepatocellular carcinoma activity of Sorbaria sorbifolia by regulating VEGFR and c-Met/apoptotic pathway

Inhibition of the Wnt/β-catenin Signaling Pathway Improves the Anti-Tumor Effects of Sorafenib Against Hepatocellular Carcinoma.

Abstract 2052: WNT/beta-catenin signaling inhibitors improve the anti-proliferative effect of sorafenib against hepatocellular carcinoma (HCC) cells.

Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism

Mechanism study of protobioside on tumor cell proliferation

Study on the molecular mechanisms of sorafenib inhibiting human peripheral blood T cells

Effects of PolyphyllinⅡ in Growth Inhibition of Human Breast Cancer Cells

Berbamine Induces Fas-Mediated Apoptosis in Human Hepatocellular Carcinoma Hepg2 Cells and Inhibits Its Tumor Growth in Nude Mice

Effect of Anti-Cancer Mechanism of Sorafenib Combined with Taxol on A549/Taxol Cell Line of Lung Cancer in Vitro

Inhibitory effect of saikosaponins-d on human hepatocellular carcinoma cell line SMMC-7721 proliferation

Effect of ursolic acid on proliferation and apoptosis of hepatic carcinoma HepG2 cell line and its partial mechanism

[Effects of Sorafenib on Proliferation and Apoptosis of Human Multiple Myeloma Cell RPMI 8226].

Sorafenib inhibition of hepatic stellate cell activation in the microenvironment of hepatocellular carcinoma

In Vitro Inhibitory Effect of Sorafenib on Proliferation of Human Hepatocellular Carcinoma Cells with Differential Perk Expression Reinforced by Lentivirus-Mediated Small RNA Interference Targeting MIM-B Gene

Effects of Berberine on the Proliferation of Human Pulmonary Carcinoma Cells

The mechanism of Grifola polysaccharide inhibiting hepatocellular carcinoma cells